|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Alnylam Pharmaceuticals Inc., of Cambridge, Mass., obtained rights to RNAi delivery technology developed in the laboratory of Judy Lieberman from the CBR Institute for Biomedical Research, a Harvard Medical School affiliate. The technology may enable small interfering RNAs to be targeted with an engineered monoclonal antibody to tumors and other cell types, thereby broadening the scope of Alnylam's delivery technologies for RNAi therapeutics. In addition, Alnylam recently entered two relationships providing access to technologies for the systemic delivery of RNAi therapeutics, one with Inex Pharmaceuticals Corp., of Vancouver, British Columbia, and the other with the ...